BUSINESS COMBINATION - Narrative (Details) $ / shares in Units, $ in Thousands		12 Months Ended
	Sep. 16, 2024 USD ($) contingentValueRight $ / shares	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Business acquisition
Selling, general and administrative expenses		$ 249,636	$ 161,697	$ 124,044
Research and Development		44,581	34,286	$ 22,318
Goodwill		59,990	$ 28,221
Business combination, pro forma information, revenue of acquiree since acquisition date, actual		31,500
Business combination, pro forma information, earnings or loss of acquiree since acquisition date, actual		(14,400)
Alimera Sciences, Inc
Business acquisition
Common Stock, par value (in dollars per share) | $ / shares	$ 0.01
Cash consideration per share (in dollars per share) | $ / shares	$ 5.50
Business combination, number of contingent value rights to be received | contingentValueRight	1
Repayment of Alimera Debt	$ 78,540
Payment of Alimera transaction costs	20,172
Payment of settlement of acquiree's equity awards	19,300
Cash paid at closing for settlement of equity awards	1,300
Cash settlement for pre-acquisition equity awards	9,535
Selling, general and administrative expenses		8,800
Research and Development		1,000
Fair value of CVRs	8,322
Business combination, contingent value rights	8,700
Goodwill	$ 32,202	31,765
Payment of Alimera transaction costs		12,400
Alimera Sciences, Inc | Contingent Value Right
Business acquisition
Selling, general and administrative expenses		$ 400